Tempest Therapeutics announces $4.6 million registered direct offering

Tempest Therapeutics (TPST) has entered a definitive agreement for a registered direct offering of 739,000 shares at $6.25 per share to a single institutional investor, expecting to raise $4.6 million in gross proceeds. The funds will primarily support the company's strategic alternative process and general working capital, as Tempest previously expressed concerns about its ability to continue as a going concern in its May 2025 SEC filing. This follows the termination of its ATM prospectus supplement with Jefferies and coincides with recent Orphan Drug Designations from the EMA and FDA for its cancer treatment drugs, amezalpat and TPST-1495, respectively.

Analysis

Tempest Therapeutics, Inc. (TPST) is undertaking a registered direct offering of 739,000 common shares at $6.25 per share, aiming to raise approximately $4.6 million in gross proceeds. This offering price represents a significant discount to its recent trading price of $8.88, a level achieved after a 28.79% return over the past week. The capital injection is primarily intended to support the company's previously announced strategic alternative process and for general working capital, which is critical given the company’s May 13, 2025, SEC filing that indicated concerns about its ability to continue as a going concern and InvestingPro analysis highlighting rapid cash burn. This financing initiative follows the termination of its automatic teller machine (ATM) prospectus supplement. Despite these financial pressures, Tempest has recently achieved positive milestones: it regained compliance with Nasdaq's minimum bid price requirement, and its drug candidates amezalpat and TPST-1495 received Orphan Drug Designations from the European Medicines Agency and/or the U.S. Food and Drug Administration for hepatocellular carcinoma and Familial Adenomatous Polyposis, respectively. A Phase 2 study for TPST-1495, funded by the National Cancer Institute, is planned with results anticipated in 2026, indicating ongoing efforts to advance its clinical pipeline.

Key Decisions for Investors

• Investors should carefully evaluate the immediate dilutive effect of the share offering conducted at a substantial discount to the recent market price, against the necessity of the capital for addressing going concern issues and funding the strategic alternative process.
• While the recent Orphan Drug Designations for amezalpat and TPST-1495 are positive long-term catalysts, the company's high cash burn rate and financial stability remain key risks to monitor closely.
• Consider the potential outcomes of the ongoing strategic alternative process as a significant factor for future valuation, alongside the clinical development progress, particularly the upcoming Phase 2 results for TPST-1495 expected in 2026.